We look after women’s health globally by setting trends in female fertility, uterine fibroids / endometriosis, female contraception, vaginal infections, menopause and female technology.
Key strategic goal: By addressing unmet needs and staying ahead of innovation we aim to become the leading provider of pharmaceutical products for European women by the end of the decade.
Therapeutic area: Women’s Healthcare
Leveraging our world class early phase R&D capability in the central nervous system domain we build a pipeline of small molecule drug candidates mainly in the field of neuropsychiatry.
Key strategic goal: Maximize the potential of cariprazine, while developing and partnering original R&D projects that provide the basis for revenue and earnings growth beyond 2030.
Therapeutic area: Neuropsychiatry
Leverage our biotechnology platform to develop and manufacture biosimilar drugs for global markets.
Key strategic goal: By establishing ourselves as a relevant player in the Rheumatology/Osteoporosis TA, we aim to become a solid contributor to corporate profits by the end if this decade. We leverage our biotechnology expertise in providing value to third party clients through our contract development and manufacturing services.
Therapeutic area: Rheumatology, Osteoporosis
Comprises our established and generic portfolio in various therapeutic areas in the Central and Eastern European regions.
Key strategic goal: Provide broad access to high quality and affordable medications while remaining a reliable source of revenue growth, scale and margins.
Therapeutic area: Cardiology, Blood, Diabetes, CNS